DYAI — Dyadic International, Inc.

Dyadic International Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Total Revenue: Approximately $1.1 million, a 182% increase from $394,000 in Q1 2025.
• Revenue Breakdown:
  • Research and development revenue: $220,000.
  • Grant revenues: $277,000 (from CEPI and the Gates Foundation).
  • Milestone revenue: $200,000 (from Inzymes Agreement).
• Cost of Revenue: Approximately $792,000, up from $298,000 in the prior year, primarily due to increased R&D activity.
• Loss from Operations: Improved to approximately $1.9 million from $2 million year-over-year.
• Net Loss: Approximately $1.95 million ($0.05 per share), compared to $2.03 million ($0.07 per share) in Q1 2025.
• Cash Position: Ended the quarter with approximately $6.6 million in cash and equivalents, with a cash runway projected into Q2 2027.

2. Strategic Updates and Business Highlights

• Transitioning from a platform technology company to a commercially focused biotechnology firm.
• Successful product launches and partnerships, including:
  • Proliant Health & Biologics' launch of Albufree Dx recombinant human albumin.
  • Inzymes' commercialization of recombinant non-animal bovine chymosin.
• Expansion of customer engagement in life sciences, particularly with recombinant bovine transferrin and DNase-1.
• New OEM distribution agreement with IBT Bioservices to market Dyadic products globally.
• Focus on animal-free proteins and enzymes across life sciences, food, nutrition, and industrial applications.

3. Forward Guidance and Outlook

• Anticipated growth in product revenues across Life Sciences and Food and Nutrition sectors due to recent launches and increasing customer engagement.
• Continued focus on building recurring revenue opportunities while managing expenses in line with 2025 levels.
• Expectation of sustained revenue growth as products move through the commercialization pipeline.

4. Bad News, Challenges, or Points of Concern

• The company is still perceived as being in transition, which may affect investor sentiment.
• While revenue growth is strong, the company acknowledges that it is still early in the commercialization phase, and significant growth may take time.
• Regulatory approvals for cultured meat and other products remain a potential hurdle, impacting the speed of market entry.
• Increased operational costs associated with scaling up production and distribution.

5. Notable Q&A Insights

• Recombinant Bovine Transferrin: Expected to see steady growth, but not explosive; growth will depend on regulatory approvals and market adoption in both cultivated meat and other applications.
• Biopharmaceutical Opportunities: The C1 platform is positioned to respond quickly to emerging health crises, such as Hantavirus, with improved technology since the COVID-19 pandemic.
• Partnerships: The relationship with Intralink is expanding, enhancing business development capabilities in Asia and Europe.
• Cash Burn: Expected to remain consistent with previous years, allowing for sufficient cash runway into 2027.
• Regulatory Landscape: The U.S. is seen as having a more favorable regulatory environment for cultured meat compared to the EU.

Overall, Dyadic International is making significant strides in commercializing its technology and products while navigating the challenges of transitioning from a research-focused entity to a revenue-generating biotechnology company.